Recruitment

Recruitment Status
Completed
Estimated Enrollment
249

Summary

Conditions
Infections, Meningococcal
Type
Interventional
Phase
Phase 3
Design
  • Allocation: Randomized
  • Intervention Model: Single Group Assignment
  • Masking: None (Open Label)
  • Primary Purpose: Prevention

Participation Requirements

Age
Younger than 125 years
Gender
Both males and females

Description

The subjects in this study will be allocated to the same groups as in study MENACWY-TT-048 EXT: 039 Y2, 3, 4, 5 (NCT00955682). No vaccine will be administered during this long-term persistence study.

The subjects in this study will be allocated to the same groups as in study MENACWY-TT-048 EXT: 039 Y2, 3, 4, 5 (NCT00955682). No vaccine will be administered during this long-term persistence study.

Locations

Vantaa, 01300
Helsinki, 00100
Turku, 20520
Espoo, 02230
Oulu, 90220
...
Vantaa, 01300
Helsinki, 00100
Turku, 20520
Espoo, 02230
Oulu, 90220
Tampere, 33100
Seinajoki, 60100
Jarvenpaa, 60100
Pori, 28100
Helsinki, 00930

Tracking Information

NCT #
NCT01900899
Collaborators
Not Provided
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer